It has been a turbulent few days for shares in Ireland-headquartered Perrigo (NYSE: PRGO) as word that it might be taken over by a UK-based company prompted rumors and counter-rumors.
A source from finance website StreetInsider claimed on Tuesday that the consumer and generic drug firm was close to being bought for $20 million.
This prompted Perrigo’s share price to rocket that day by 9% as investors jumped on the speculation, about which the company declined to comment. On Wednesday the share price promptly dropped by 9% as analysts considered the likelihood of the takeover going ahead.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze